rivaroxaban 20 mg once daily 8 days
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bariatric Surgery
Conditions
Bariatric Surgery, Morbid Obesity
Trial Timeline
Jan 15, 2020 → Jun 27, 2022
NCT ID
NCT04180436About rivaroxaban 20 mg once daily 8 days
rivaroxaban 20 mg once daily 8 days is a phase 1 stage product being developed by Bayer for Bariatric Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT04180436. Target conditions include Bariatric Surgery, Morbid Obesity.
What happened to similar drugs?
1 of 3 similar drugs in Bariatric Surgery were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04180436 | Phase 1 | Completed |
Competing Products
9 competing products in Bariatric Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (INN imapextide) | MBX Biosciences | Phase 2 | 36 |
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 23 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| Esomeprazole | AstraZeneca | Approved | 43 |
| Rivaroxaban 10 MG Oral Tablet [Xarelto] | Bayer | Phase 2 | 32 |
| Pasireotide Diaspartate | Recordati | Phase 2 | 36 |
| Avexitide | Amylyx Pharmaceuticals | Phase 3 | 38 |
| glucagon | Xeris Pharmaceuticals | Phase 1/2 | 26 |
| ARD-101 | Aardvark Therapeutics | Phase 2 | 25 |